With 0.57 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.43 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $14.47 whereas the lowest price it dropped to was $13.79. The 52-week range on DCTH shows that it touched its highest point at $14.10 and its lowest point at $3.70 during that stretch. It currently has a 1-year price target of $21.86. Beta for the stock currently stands at 0.84.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DCTH was up-trending over the past week, with a rise of 24.65%, but this was up by 17.10% over a month. Three-month performance surged to 50.47% while six-month performance rose 92.60%. The stock gained 271.69% in the past year, while it has gained 18.85% so far this year. A look at the trailing 12-month EPS for DCTH yields -1.36 with Next year EPS estimates of -0.02. For the next quarter, that number is 0.00. This implies an EPS growth rate of 73.40% for this year and 97.87% for next year.
Float and Shares Shorts:
At present, 28.02 million DCTH shares are outstanding with a float of 26.99 million shares on hand for trading. On 2024-10-15, short shares totaled 1.25 million, which was 446.0 higher than short shares on 1726185600. In addition to Mr. Gerard J. Michel MBA, MS as the firm’s CEO & Director, Ms. Sandra Pennell serves as its Senior VP of Finance and Principal Financial & Accounting Officer.
Institutional Ownership:
Through their ownership of 0.38127998 of DCTH’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, DCTH reported revenue of $11200000.0 and operating income of -$1259000.0. The EBITDA in the recently reported quarter was -$4136000.0 and diluted EPS was $0.06.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DCTH since 7 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DCTH analysts setting a high price target of 25.0 and a low target of 20.0, the average target price over the next 12 months is 21.83333. Based on these targets, DCTH could surge 74.7% to reach the target high and rise by 39.76% to reach the target low. Reaching the average price target will result in a growth of 52.57% from current levels.
Analysts have provided yearly estimates in a range of -$0.67457 being high and -$0.87987 being low. For DCTH, this leads to a yearly average estimate of -$0.78211. Based on analyst estimates, the high estimate for the next quarter is $0.01 and the low estimate is -$0.17. The average estimate for the next quarter is thus -$0.05.
